mardi 17 novembre 2026
RechercherExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each, so you can check any claim. How we source
Source document· December 12, 2025

Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer

View original at finance.yahoo.com
Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer As monotherapy, imlunestrant demonstrated an 11.4-month numeric improvement in median OS versus endocrine therapy in patients with ESR1-mutated…
Opening lines of the source · short snapshot: read the full document at the original

Ce que nous avons tiré de cette source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Breast cancer is the 2nd most diagnosed cancer worldwide after lung cancer

    80% confidence
  • Updated EMBER-3 data demonstrate continued clinically meaningful benefit for patients receiving monotherapy and those receiving the combination with abemaciclib, reinforcing Inluriyo's role in the treatment setting

    80% confidence
  • With an additional year of follow-up, EMBER-3 results strengthen the case for imlunestrant-based regimens in ER+, HER2– metastatic breast cancer

    80% confidence
  • Eli Lilly is encouraged by the potential of an all-oral combination with imlunestrant and abemaciclib

    80% confidence
  • The median progression-free survival of 11 months is among the longest seen in ER+, HER2– metastatic breast cancer population

    80% confidence
  • Eli Lilly medicines help tens of millions of people globally

    80% confidence
Updated data for Lilly's Inluriyo™ (imlunestrant) reinforce efficacy results as monotherapy and in combination with Verzenio® (abemaciclib) in ER+, HER2- advanced breast cancer: Source | Via News | fr.via.news